EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PRDX6 Drives Breast Cancer Progression Through Mitochondrial Biosynthesis and Oxidative Phosphorylation

Mei Dai, Danhua Zhang iD

Cancer Medicine · 2025-07 · 14 (13)

DOI: 10.1002/cam4.71005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 30.06.2025. Verfasst von Mei Dai und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Mitochondria, Oxidative Phosphorylation, Peroxiredoxin VI. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Peroxiredoxin 6 (PRDX6) scavenges reactive oxygen species (ROS) and plays a key role in antioxidant defense. Although PRDX6 is involved in various cancers, its role in breast cancer (BRCA) remains unclear.

Methods

Cell proliferation was assessed using CCK‐8, EdU staining, and colony formation assays. Migration and invasion were evaluated via wound‐healing and transwell assays. ROS levels and mitochondrial membrane potential were measured by fluorescence microscopy or flow cytometry. Oxidative phosphorylation (OXPHOS) activity was determined by ATP production and NAD + /NADH ratio. Mitochondria were visualized by TEM, and mitochondrial complex subunits were detected by quantitative real‐time PCR and Western blotting. In vivo effects were evaluated using a xenograft tumor model.

Results

Although PRDX6 was downregulated in BRCA overall, it showed elevated expression in aggressive subtypes and advanced‐stage tumors, correlating with poor prognosis. Overexpression of PRDX6 enhanced BRCA cell proliferation, migration, and invasion. PRDX6 reduced ROS levels, upregulated mitochondrial transcription factor A (TFAM) expression, and promoted mitochondrial complex subunit expression and OXPHOS. Inhibition of TFAM led to a decrease in the expression of some of the mitochondrial complex subunits, which reversed the pro‐carcinogenic phenotype of the tumor. PRDX6 also promoted tumor growth in vivo.

Conclusion

PRDX6 maintains intracellular homeostasis by reducing ROS and promotes mitochondrial biogenesis and OXPHOS through TFAM‐dependent and ‐independent pathways, driving BRCA progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMitochondriaOxidative PhosphorylationPeroxiredoxin VIHumansFemaleAnimalsMiceCell ProliferationReactive Oxygen SpeciesCell MovementDisease ProgressionCell Line, TumorGene Expression Regulation, NeoplasticMice, NudePrognosis

Stichwörter der Autor:innen

PRDX6breast cancermitochondriaoxidative phosphorylation (OXPHOS)tumorigenesis

Substanzen

Peroxiredoxin VIReactive Oxygen SpeciesPRDX6 protein, human

Autor:innen und Institutionen

  • Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Clinical Research Center for Breast Disease of Hunan Province, Changsha, Hunan, China.

ORCID-Profile: Danhua Zhang

Zitieren

APA

Dai, M., & Zhang, D. (2025). PRDX6 Drives Breast Cancer Progression Through Mitochondrial Biosynthesis and Oxidative Phosphorylation. Cancer Medicine, 14(13). https://doi.org/10.1002/cam4.71005

Vancouver

Dai M, Zhang D. PRDX6 Drives Breast Cancer Progression Through Mitochondrial Biosynthesis and Oxidative Phosphorylation. Cancer Medicine. 2025;14(13). doi:10.1002/cam4.71005

BibTeX
@article{Dai2025,
  author = {Dai, Mei and Zhang, Danhua},
  title = {PRDX6 Drives Breast Cancer Progression Through Mitochondrial Biosynthesis and Oxidative Phosphorylation},
  journal = {Cancer Medicine},
  year = {2025},
  volume = {14},
  number = {13},
  doi = {10.1002/cam4.71005}
}
Kostenlos starten →